RCM
SGMO

Riverhead Capital Management’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Riverhead Capital Management’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-1,940
Closed -$22K – 1509
2018
Q4 		$22K Sell
1,940
-2,600
-57% -$32.3K ﹤0.01% 1459
2018
Q3 		$77K Sell
4,540
-3,727
-45% -$56.6K ﹤0.01% 1438
2018
Q2 		$117K Buy
8,267
+5,667
+218% +$94.1K ﹤0.01% 1291
2018
Q1 		$49K Buy
+2,600
New +$55.6K ﹤0.01% 1467

Other funds holding SGMO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Riverhead Capital Management's SGMO Position: Q1 2019 in Review

Riverhead Capital Management sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q1 2019, closing a stake of 1,940 shares — an estimated $22K sold.

Riverhead Capital Management first reported a position in SGMO in Q1 2018 and held it in 4 quarters. The position peaked at $117K in Q2 2018. 187 funds tracked by Wall St. Rank hold SGMO as of Q1 2019.

  • Riverhead Capital Management reported no remaining SANGAMO THERAPEUTICS INC position as of Q1 2019 after selling out during the quarter.
  • Riverhead Capital Management sold 1,940 SANGAMO THERAPEUTICS INC shares in Q1 2019, an estimated $22K.
  • Riverhead Capital Management first reported a position in SANGAMO THERAPEUTICS INC in Q1 2018 and held it in 4 quarters.
  • Riverhead Capital Management's SANGAMO THERAPEUTICS INC position peaked at $117K in Q2 2018.
  • 187 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q1 2019.

Based on Riverhead Capital Management's 13F filing for Q1 2019, filed 13 May 2019.